Saturday
SESSION 43: LUNCHEON SESSION: NEW OR IMPROVED ENDOVASCULAR DEVICES (5-MINUTE TALKS)
SESSION 43 SCHEDULE
PLENARY SESSIONS (SESSIONS 39 - 45) - LOCATION: GRAND BALLROOM, 3RD FLOOR
12:00 PM - 12:05 PM Latest Generation AAA Stent-Grafts Are Being Heralded As Important Advances: Are We Too Quick To Embrace Unproven Technology
  Presenter(s):Frank J. Criado, MD, FACS, FSVM  
12:06 PM - 12:11 PM The Cordis INCRAFT AAA Endograft: A Lower Profile Device: Advantages And Disadvantages
  Presenter(s):Jan S. Brunkwall, MD, PhD  
12:12 PM - 12:17 PM Experience With The TriVascular OVATION AAA Endograft: Results Of The Pivotal U.S. And Out Of U.S. Trials With A Unique Lower Profile Device
  Presenter(s):Francisco Valdes, MD / Michael D. Dake, MD  
12:18 PM - 12:23 PM Advantages And Benefits Of The New C3 Gore Excluder AAA Graft - Does The Ability To Reposition Make A Difference: The European And U.S. Experience
  Presenter(s):Eric L.G. Verhoeven, MD, PhD / Mark F. Fillinger, MD  
12:24 PM - 12:29 PM Clinical Experience With The Endologix (VENTANA) Off-The-Shelf Fenestrated Device For Juxtarenal AAAs: Advantages And Limitations
  Presenter(s):Daniel G. Clair, MD  
12:30 PM - 12:35 PM World And U.S. Experience With The Nellix Device For EVAR: A New Concept With Polymer Filled Bags Obliterating The AAA Sac And Maintaining Flow With Stents: Advantages, Limitations And Midterm Results
  Presenter(s):Clifford J. Buckley, MD / Andrew Holden, MBChB / Carlos E. Donayre, MD  
12:36 PM - 12:41 PM ANACONDA Fenestrated Endograft For Juxtarenal AAAs: Principles And Clinical Experience
  Presenter(s):Peter M. Bungay, MBChB  
12:42 PM - 12:47 PM U.S. Pivotal Trial Results With The ANACONDA Device For EVAR: Advantages And Limitations
  Presenter(s):Christopher J. Kwolek, MD  
12:48 PM - 12:53 PM U.S. Pivotal Trial And Other Experience With The AORFIX Device: Advantages And Limitations
  Presenter(s):Mark F. Fillinger, MD  
12:54 PM - 1:00 PM Panel Discussion
END OF SESSION 43
previous next